基本數據
| CIK | 1575142 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioAdaptives, Inc.
SEC Filings (Chronological Order)
本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 Commission File Number 000-54949 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction of incorporation or organizat |
|
| April 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark one) ☒ Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2025 ☐ Transition Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54949 BioAdaptives, Inc. |
|
| March 31, 2026 |
OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response................. 2.50 FORM 12b-25 SEC FILE NUMBER NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2025 |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 Commission File Number 000-54949 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction of incorporation or organ |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Commission File Number 000-54949 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction of incorporation or organizati |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Commission File Number 000-54949 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction of incorporation or organizat |
|
| April 15, 2025 |
James E Keener Employment Agreement EXHIBIT 10.1 James E. Keener Employment agreement: Chief Executive Officer Employment Contract This agreement, made and effective as of the 21st day of May, 2024 between BioAdaptives, Inc, a Delaware corporation (‘‘Company’’), and James Keener. WHEREAS, the Company desires to secure the services of the CEO and the CEO desires to accept such employment. NOW ‘l’HEREFORE, in consideration of the mate |
|
| April 15, 2025 |
Articles of Incorporation (with amendments) EXHIBIT 3.1 CERTIFICATE OF AMENDMENT |
|
| April 15, 2025 |
EXHIBIT 10.2 BOARD OF DIRECTORS AGREEMENT This Board of Directors Agreement (“Agreement”) made effective as May 27, 2024, by and between BioAdaptives, Inc., with its principal place of business at 2620 Regatta Dr, Suite 102, Las Vegas, NV 89128 (the “Company”) and Gimhana Dissanayake, with an address at 2517 Cattrack Ave, North Las Vegas, NV 89081 (“Director”), provides for director services, acco |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark one) ☒ Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 ☐ Transition Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54949 BioAdaptives, Inc. |
|
| March 31, 2025 |
OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response................. 2.50 FORM 12b-25 SEC FILE NUMBER NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: Preliminary Information Statement Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement BIOADAPTIVES, INC. |
|
| March 18, 2025 |
Zeranovia™ Weight Loss Product Shows Promising Results in Dosage Trial EXHIBIT 99.1 Zeranovia™ Weight Loss Product Shows Promising Results in Dosage Trial LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) - via IBN - BioAdaptives Inc. (OTC: BDPT) today announced the successful completion of dosage trials for its innovative weight loss product, Zeranovia™. The trial demonstrated significant weight loss results with minimal side effects, marking a crucial product development |
|
| March 18, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13,2025 BIOADAPTIVES, INC. |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: Preliminary Information Statement Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement BIOADAPTIVES, INC. |
|
| February 24, 2025 |
UNITED STATES OF AMERICA BEFORE THE SECURITIES AND EXCHANGE COMMISSION February 24, 2025 In the Matter of Bioadaptives, Inc. |
|
| February 7, 2025 |
BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors EXHIBIT 99.1b BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors BioAdaptives Inc. Harris, the Senior Vice President of Athlete Development and Marketing at the Ultimate Fighting Championship, has a distinguished career spanning over 40 years LAS VEGAS, Feb. 06, 2025 (GLOBE NEWSWIRE) - via IBN – BioAdaptives Inc. (OTC: BDPT), a leading biotechnology company focused on |
|
| February 7, 2025 |
FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 3, 2025 BIOADAPTIVES, INC. |
|
| February 7, 2025 |
BioAdaptives Welcomes Mark Frissora, Acclaimed Business Leader, to Its Board of Directors EXHIBIT 99.1a BioAdaptives Welcomes Mark Frissora, Acclaimed Business Leader, to Its Board of Directors BioAdaptives Inc. Frissora is recognized for his ability to lead organizations through complex challenges and deliver sustained value creation LAS VEGAS, Feb. 03, 2025 (GLOBE NEWSWIRE) - BioAdaptives, Inc. (OTC: BDPT), a pioneering health and wellness company dedicated to innovative, science-dri |
|
| December 5, 2024 |
BioAdaptives, Inc.’s Board of Directors Approves a One-for-One Stock Dividend EXHIBIT 99.1 BioAdaptives, Inc.’s Board of Directors Approves a One-for-One Stock Dividend LAS VEGAS, Dec. 03, 2024 (GLOBE NEWSWIRE) - via IBN – BioAdaptives Inc. (OTC: BDPT) Board of Directors has approved a dividend to all common stockholders. They will receive matching shares for all of the shares they own on the Record Date. CEO James Keener stated, “This dividend is designed to acknowledge yo |
|
| December 5, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 3, 2024 BIOADAPTIVES, INC. |
|
| November 27, 2024 |
EXHIBIT 99.1 BioAdaptives, Inc. Announces Institutional Review Board Approval of a Human Clinical Trial for Zeranovia™ LAS VEGAS, Nov. 25, 2024 (GLOBE NEWSWIRE) - via IBN – BioAdaptives Inc. (OTC: BDPT) received approval today for a human clinical trial of its weight management product, Zeranovia™. The trial, approved by an Institutional Review Board, will be managed and supervised by doctors in L |
|
| November 27, 2024 |
FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 26, 2024 BIOADAPTIVES, INC. |
|
| November 20, 2024 |
BioAdaptives, Inc. Letter to Shareholders Regarding the Reverse Stock Split EXHIBIT 99.1 BioAdaptives, Inc. Letter to Shareholders Regarding the Reverse Stock Split On November 20, 2024, BioAdaptives® announced that it will complete a 1-for-300 reverse stock split, a corresponding proportionate reduction in the number of shares of BioAdaptives® Inc.'s common stock (BDPT). BioAdaptives® shareholders previously approved the Reverse Stock Split at a special meeting on Septem |
|
| November 20, 2024 |
FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2024 BIOADAPTIVES, INC. |
|
| November 19, 2024 |
Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54949 BioAdaptives Inc. |
|
| November 14, 2024 |
OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response................ 2.50 FORM 12b-25 SEC FILE NUMBER NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2024 |
|
| October 30, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 28, 2024 BIOADAPTIVES, INC. |
|
| October 30, 2024 |
BioAdaptives, Inc. Letter to Shareholders Regarding the Reverse Stock Split EXHIBIT 99.1 BioAdaptives, Inc. Letter to Shareholders Regarding the Reverse Stock Split LAS VEGAS, Oct. 29, 2024 (GLOBE NEWSWIRE) - via IBN - Due to a website maintenance error, a draft of a letter to BioAdaptives® shareholders was made available on the BioAdaptives® website. While the timing was unfortunate, it raised awareness of an upcoming event critical for the long-term health of BioAdaptiv |
|
| October 22, 2024 |
BDPT / BioAdaptives, Inc. / Keener James - FORM SC 13D Activist Investment SC 13D 1 bdptsc13d.htm FORM SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ...) BioAdaptives Inc (Name of Issuer) Preferred Series C (Title of Class of Securities) N/A (CUSIP Number) James Keener, 2620 Regatta Dr, Suite 102, Las Vegas, NV 89128 702-659-8829 (Name, Address and Telephone Number of P |
|
| October 22, 2024 |
Purchase agreement BioAdaptives and Azuna Health Signed.pdf EX-1 2 bdptex1.htm PURCHASE AGREEMENT EXHIBIT 1 PURCHASE AGREEMENT This Agreement is made this 18th. day of April, 2024, by and between Azuna Health, LLC., a Nevada LLC (“Azuna” or “Seller”) with its principal offices in Las Vegas, Nveada, and Bioadaptives, Inc., a Delaware corporation (“Bioadaptives” or “Buyer”) with its principal offices in Las Vegas, Nevada. WHEREAS, Seller is the exclusive own |
|
| October 22, 2024 |
Purchase agreement BioAdaptives and Azuna Health Signed.pdf EX-1 2 bdptex1.htm PURCHASE AGREEMENT EXHIBIT 1 PURCHASE AGREEMENT This Agreement is made this 18th. day of April, 2024, by and between Azuna Health, LLC., a Nevada LLC (“Azuna” or “Seller”) with its principal offices in Las Vegas, Nveada, and Bioadaptives, Inc., a Delaware corporation (“Bioadaptives” or “Buyer”) with its principal offices in Las Vegas, Nevada. WHEREAS, Seller is the exclusive own |
|
| October 22, 2024 |
BDPT / BioAdaptives, Inc. / Azuna Health LLC - SC 13D Activist Investment SC 13D 1 bdptsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) BioAdaptives Inc (Name of Issuer) Preferred Series C (Title of Class of Securities) N/A (CUSIP Number) James Keener, 2620 Regatta Dr, Suite 102, Las Vegas, NV 89128 702-659-8829 (Name, Address and Telephone Number of Person Au |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Commission File Number 000-54949 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction of incorporation or organizati |
|
| August 15, 2024 |
OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response................ 2.50 FORM 12b-25 SEC FILE NUMBER NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Tr |
|
| May 22, 2024 |
EXHIBIT 99.1 BioAdaptives, Inc. Appoints James Keener as New CEO to Lead Strategic Growth Initiatives LAS VEGAS, NV, May 21, 2024 (NewMediaWire) – BioAdaptives, Inc. (OTC: BDPT), a pioneer in advanced nutrition and wellness solutions, announced a significant addition to its Executive Team today. James Keener has been appointed the new CEO and will play a pivotal role in driving the company’s strat |
|
| May 22, 2024 |
FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2024 BIOADAPTIVES, INC. |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Commission File Number 000-54949 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction of (IRS Employer Identificati |
|
| May 15, 2024 |
OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response................ 2.50 FORM 12b-25 SEC FILE NUMBER NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ T |
|
| May 14, 2024 |
FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2024 BIOADAPTIVES, INC. |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark one) ☒ Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 ☐ Transition Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54949 BioAdaptives, Inc. |
|
| April 1, 2024 |
0MB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMBNumber: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response................. 2.50 FORM 12b-25 SEC FILE NUMBER NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Commission File Number 000-54949 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction of incorporation or organ |
|
| October 11, 2023 |
CERTIFICATE OF DESIGNATION ESTABLISHING EXHIBIT 2.4 |
|
| October 11, 2023 |
EXHIBIT 2.8 |
|
| October 11, 2023 |
AMENDED CERTIFICATE OF INCORPORATION EXHIBIT 2.7 |
|
| October 11, 2023 |
PO Box 281077 Nashville, TN 37228 315 Deadrick Street Nashville, TN 37203 EXHIBIT 12.1 PO Box 281077 Nashville, TN 37228 315 Deadrick Street Nashville, TN 37203 615-476-1151 [email protected] October 9, 2023 Bioadaptives Inc. 2620 Regatta Drive Suite 102 Las Vegas, NV 89128 Ladies and Gentlemen: We have acted as counsel to Bioadaptives, Inc.., a Delaware corporation (the “Company”) in connection with the Company’s Regulation A Offering Statement on Form 1-A (the “ |
|
| October 11, 2023 |
AMENDED CERTIFICATE OF INCORPORATION EXHIBIT 2.5 |
|
| October 11, 2023 |
EXHIBIT 11.1 |
|
| October 11, 2023 |
As filed with the Securities and Exchange Commission on October 9, 2023 PART II - INFORMATION REQUIRED IN OFFERING CIRCULAR Preliminary Offering Circular dated October 9, 2023 An offering statement pursuant to Regulation A relating to these securities has been filed with the United States Securities and Exchange Commission (the “SEC”). |
|
| October 11, 2023 |
EXHIBIT 2.3 |
|
| October 11, 2023 |
EXHIBIT 2.2 |
|
| October 11, 2023 |
EXHIBIT 6.4 |
|
| October 11, 2023 |
EXHIBIT 6.3 |
|
| October 11, 2023 |
RESOLUTION OF THE DIRECTORS OF BREATH OF LIFE FOUNDATION (WY 2016-000736983) EXHIBIT 99.3 RESOLUTION OF THE DIRECTORS OF BREATH OF LIFE FOUNDATION (WY 2016-000736983) The undersigned constitute a quorum of the directors of Breath of Life Foundation, a non-profit organization formed under provision of the Wyoming Non-Profit Corporation Act (the “Foundation”). The following minutes and resolutions set out the results of a telephonic meeting held on April 26, 2022. 1. The dir |
|
| October 11, 2023 |
EXHIBIT 99.2 April 14, 2022 Ferris Holding, Inc 2251 N. Rampart Blvd., #182 Las Vegas, NV 89128 Re: License Agreements dated October 21, 2013 Dear Sirs: BioAdaptives, Inc. entered into two separate license agreements with Ferris Holding on October 21, 2013, permitting usage of Ferris’ Agronifier™ and related technology and proprietary products. These licenses each covered an initial six (6) month |
|
| October 11, 2023 |
EXHIBIT 99.1 Irrevocable Proxy The Stockholder hereby revokes any and all previous proxies and powers of attorney granted with respect to such Stockholder's Shares, and the Stockholder shall not grant any subsequent proxy or power of attorney with respect to such Stockholder's Shares, as agreed herein, The Stockholder hereby grants, or agrees to cause the applicable record holder to grant, a proxy |
|
| October 11, 2023 |
EXHIBIT 6.1 |
|
| October 11, 2023 |
PRODUCT LICENSE WITH FERRIS HOLDING EXHIBIT 6.2 |
|
| October 11, 2023 |
PATENT PURCHASER AGREEMENT AND CONSULTING AGREEMENT EXHIBIT 6.5 |
|
| October 11, 2023 |
EXHIBIT 6.6 |
|
| October 11, 2023 |
EXHIBIT 2.1 |
|
| October 11, 2023 |
AMENDED CERTIFICATE OF INCORPORATION EXHIBIT 2.6 |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Commission File Number 000-54949 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction of incorporation or organizati |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Commission File Number 000-54949 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction of incorporation or organizat |
|
| April 6, 2023 |
Amended Certificate of Incorporation EXHIBIT 3.1 |
|
| April 6, 2023 |
EXHIBIT 99.1 BioAdaptives, Inc. (OTC BDPT) Announces New Appointment to the Board of Directors - Internationally Acclaimed Health Scientist, Author and Patent Holder, Dr. Yaguang Liu LAS VEGAS, NV, April 05, 2023 (GLOBE NEWSWIRE) - via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT) announced today the appointment of Dr.Yaguang Liu to its Board of Directors. Edward Jacobs, M.D., CEO Bioadaptives |
|
| April 6, 2023 |
FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 6, 2023 BIOADAPTIVES, INC. |
|
| March 31, 2023 |
Articles of Incorporation (with amendments) EXHIBIT 3.1 |
|
| March 31, 2023 |
Now UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K Now UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark one) ☒ Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 ☐ Transition Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54949 BioAdaptives, Inc. |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: Preliminary Information Statement Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement BIOADAPTIVES, INC. |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement BIOADAPTIVES, INC. |
|
| November 15, 2022 |
BIOADAPTIVES, INC. 2620 Regatta Drive, Suite 102 Las Vegas, Nevada 89128 BIOADAPTIVES, INC. 2620 Regatta Drive, Suite 102 Las Vegas, Nevada 89128 November 15, 2022 VIA EDGAR Ada D. Sarmento Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Bioadaptives, Inc. Post Qualification Amendment No 1 to Offering Statement on Form 1A Commission File No. 024-11819 Dear Ms Sarmento: On behalf of |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Commission File Number 000-54949 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction of incorporation or organ |
|
| November 8, 2022 |
As filed with the Securities and Exchange Commission on October 28, 2022 PART II - INFORMATION REQUIRED IN OFFERING CIRCULAR Preliminary Offering Circular dated October 7, 2022 An offering statement pursuant to Regulation A relating to these securities has been filed with the United States Securities and Exchange Commission (the “SEC”). |
|
| November 8, 2022 |
EXHIBIT 99.2 April 14, 2022 Ferris Holding, Inc 2251 N. Rampart Blvd., #182 Las Vegas, NV 89128 Re: License Agreements dated October 21, 2013 Dear Sirs: BioAdaptives, Inc. entered into two separate license agreements with Ferris Holding on October 21, 2013, permitting usage of Ferris’ Agronifier™ and related technology and proprietary products. These licenses each covered an initial six (6) month |
|
| November 8, 2022 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 11.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation in this Offering Statement on Form 1-A of our report dated March 30, 2022, relating to the financial statements of BioAdaptives, Inc. as of December 31, 2021 and 2020 and to all references to our firm included in this Registration Statement. Certified Public Accountants Lakewood, CO October |
|
| November 8, 2022 |
EXHIBIT 99.1 Irrevocable Proxy. The Stockholder hereby revokes any and all previous proxies and powers of attorney granted with respect to such Stockholder's Shares, and the Stockholder shall not grant any subsequent proxy or power of attorney with respect to such Stockholder's Shares, as agreed herein, The Stockholder hereby grants, or agrees to cause the applicable record holder to grant, a prox |
|
| November 8, 2022 |
RESOLUTION OF THE DIRECTORS OF BREATH OF LIFE FOUNDATION (WY 2016-000736983) EXHIBIT 99.3 RESOLUTION OF THE DIRECTORS OF BREATH OF LIFE FOUNDATION (WY 2016-000736983) The undersigned constitute a quorum of the directors of Breath of Life Foundation, a non-profit organization formed under provision of the Wyoming Non-Profit Corporation Act (the “Foundation”). The following minutes and resolutions set out the results of a telephonic meeting held on April 26, 2022. 1. The dir |
|
| November 8, 2022 |
PO Box 281077 Nashville, TN 37228 315 Deadrick Street Nashville, TN 37203 CORRESP 12 filename12.htm PO Box 281077 Nashville, TN 37228 315 Deadrick Street Nashville, TN 37203 615-476-1151 [email protected] October 26, 2022 Bioadaptives , Inc. 2620 Regatta Drive Suite 102 Las Vegas, NV 89128 Ladies and Gentlemen: We have acted as counsel to Bioadaptives, Inc., a Nevada corporation (the "Company") in connection with the Company's Regulation A Offering Statement on Fo |
|
| October 31, 2022 |
United States securities and exchange commission logo October 31, 2022 Edward E. Jacobs, Jr. Chief Executive Officer Bioadaptives, Inc. 2620 Regatta Drive Suite 102 Las Vegas, NV 89128 Re: Bioadpatives, Inc. Amendment No. 1 to Post-Qualification Amendment No. 1 to Offering Statement on Form 1-A Filed October 28, 2022 File No. 024-11819 Dear Edward E. Jacobs: We have reviewed your amendment and hav |
|
| October 28, 2022 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 11.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation in this Offering Statement on Form 1-A of our report dated March 30, 2022, relating to the financial statements of BioAdaptives, Inc. as of December 31, 2021 and 2020 and to all references to our firm included in this Registration Statement. Certified Public Accountants Lakewood, CO October |
|
| October 28, 2022 |
As filed with the Securities and Exchange Commission on October 28, 2022 PART II - INFORMATION REQUIRED IN OFFERING CIRCULAR Preliminary Offering Circular dated October 7, 2022 An offering statement pursuant to Regulation A relating to these securities has been filed with the United States Securities and Exchange Commission (the “SEC”). |
|
| October 28, 2022 |
RESOLUTION OF THE DIRECTORS OF BREATH OF LIFE FOUNDATION (WY 2016-000736983) EXHIBIT 99.3 RESOLUTION OF THE DIRECTORS OF BREATH OF LIFE FOUNDATION (WY 2016-000736983) The undersigned constitute a quorum of the directors of Breath of Life Foundation, a non-profit organization formed under provision of the Wyoming Non-Profit Corporation Act (the “Foundation”). The following minutes and resolutions set out the results of a telephonic meeting held on April 26, 2022. 1. The dir |
|
| October 28, 2022 |
EXHIBIT 99.2 April 14, 2022 Ferris Holding, Inc 2251 N. Rampart Blvd., #182 Las Vegas, NV 89128 Re: License Agreements dated October 21, 2013 Dear Sirs: BioAdaptives, Inc. entered into two separate license agreements with Ferris Holding on October 21, 2013, permitting usage of Ferris’ Agronifier™ and related technology and proprietary products. These licenses each covered an initial six (6) month |
|
| October 28, 2022 |
PO Box 281077 Nashville, TN 37228 315 Deadrick Street Nashville, TN 37203 PO Box 281077 Nashville, TN 37228 315 Deadrick Street Nashville, TN 37203 615-476-1151 Steve@SteveMillslaw. |
|
| October 28, 2022 |
EXHIBIT 99.1 Irrevocable Proxy. The Stockholder hereby revokes any and all previous proxies and powers of attorney granted with respect to such Stockholder's Shares, and the Stockholder shall not grant any subsequent proxy or power of attorney with respect to such Stockholder's Shares, as agreed herein, The Stockholder hereby grants, or agrees to cause the applicable record holder to grant, a prox |
|
| October 28, 2022 |
PO Box 281077 Nashville, TN 37228 315 Deadrick Street Nashville, TN 37203 PO Box 281077 Nashville, TN 37228 315 Deadrick Street Nashville, TN 37203 615-476-1151 Steve@SteveMillslaw. |
|
| October 20, 2022 |
United States securities and exchange commission logo October 20, 2022 Edward E. Jacobs, Jr. Chief Executive Officer Bioadaptives, Inc. 2620 Regatta Drive Suite 102 Las Vegas, NV 89128 Re: Bioadpatives, Inc. Post-Qualification Amendment No. 1 to Offering Statement on Form 1-A Filed October 7, 2022 File No. 024-11819 Dear Edward E. Jacobs: We have reviewed your amendment and have the following comm |
|
| October 7, 2022 |
EXHIBIT 99.1 Irrevocable Proxy. The Stockholder hereby revokes any and all previous proxies and powers of attorney granted with respect to such Stockholder's Shares, and the Stockholder shall not grant any subsequent proxy or power of attorney with respect to such Stockholder's Shares, as agreed herein, The Stockholder hereby grants, or agrees to cause the applicable record holder to grant, a prox |
|
| October 7, 2022 |
EXHIBIT 99.2 April 14, 2022 Ferris Holding, Inc 2251 N. Rampart Blvd., #182 Las Vegas, NV 89128 Re: License Agreements dated October 21, 2013 Dear Sirs: BioAdaptives, Inc. entered into two separate license agreements with Ferris Holding on October 21, 2013, permitting usage of Ferris’ Agronifier™ and related technology and proprietary products. These licenses each covered an initial six (6) month |
|
| October 7, 2022 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 11.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation in this Offering Statement on Form 1-A of our report dated March 30, 2022, relating to the financial statements of BioAdaptives, Inc. as of December 31, 2021 and 2020 and to all references to our firm included in this Registration Statement. Certified Public Accountants Lakewood, CO October |
|
| October 7, 2022 |
RESOLUTION OF THE DIRECTORS OF BREATH OF LIFE FOUNDATION (WY 2016-000736983) EXHIBIT 99.3 RESOLUTION OF THE DIRECTORS OF BREATH OF LIFE FOUNDATION (WY 2016-000736983) The undersigned constitute a quorum of the directors of Breath of Life Foundation, a non-profit organization formed under provision of the Wyoming Non-Profit Corporation Act (the “Foundation”). The following minutes and resolutions set out the results of a telephonic meeting held on April 26, 2022. 1. The dir |
|
| October 7, 2022 |
PO Box 281077 Nashville, TN 37228 315 Deadrick Street Nashville, TN 37203 PO Box 281077 Nashville, TN 37228 315 Deadrick Street Nashville, TN 37203 615-476-1151 Steve@SteveMillslaw. |
|
| October 7, 2022 |
As filed with the Securities and Exchange Commission on October 7, 2022 PART II - INFORMATION REQUIRED IN OFFERING CIRCULAR Preliminary Offering Circular dated October 7, 2022 An offering statement pursuant to Regulation A relating to these securities has been filed with the United States Securities and Exchange Commission (the “SEC”). |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Commission File Number 000-54949 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction of incorporation or organizati |
|
| June 14, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 9, 2022 BIOADAPTIVES, INC. |
|
| June 14, 2022 |
EXHIBIT 99.2 PR R2 Senior Savings . 9June 2022 BIOADAPTIVES,Inc.RevealsCorporateStrategyforaStrengthened Market Presence, Through Empowerment of Seniors, as Nutraceutical Market Surpasses $454 Billon USD As The Baby Boomer Generation Ushers in Retirement, at the Rate of About 10,000 retirees per day, Management Pursues Growth By Bringing Advanced Wellness Economically Within Reach for Over 75 Mill |
|
| June 14, 2022 |
PR DRAFT R5 Dr Sutton Research 2June2022 EXHIBIT 99.1 PR DRAFT R5 Dr Sutton Research 2June2022 BIOADAPTIVES SPONSORS COVID-19 LONG HAULER SURVEY Independent Medical Researcher to Survey use of Company Products to Relieve ?Brain Fog? and other symptoms. Las Vegas, Nevada ?June 2, 2022. BioAdaptives, Inc. (OTCMkts: BDPT) announces its sponsorship of the COVID Long Haul Survey conducted by independent medical researcher, Regina Sutton, M.D. |
|
| May 16, 2022 |
Bioadaptives, Inc. 200,000,000 Shares of Common Stock 253G1 1 bdpt253g1.htm FORM 253G1 Filed Pursuant to Rule 253(g)(1) Commission File No. 024-11819 OFFERING CIRCULAR Bioadaptives, Inc. 200,000,000 Shares of Common Stock By this Offering Circular, Bioadaptives, Inc., a Delaware corporation, is offering for sale a maximum of 200,000,000 shares of its common stock (the “Offered Shares”), at a fixed price of $0.005 per share, pursuant to Tier 2 of Regu |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Commission File Number 000-54949 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction of incorporation or organizat |
|
| May 9, 2022 |
CORRESP 1 filename1.htm May 9, 2022 VIA EDGAR Jason Drory Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Bioadaptives, Inc. Offering Statement on Form 1-A Commission File No. 024-11819 Dear Mr. Drory: On behalf of the Company, I respectfully request that the qualification date of the Offering Statement be acc |
|
| May 3, 2022 |
EXHIBIT 99.1 Irrevocable Proxy. The Stockholder hereby revokes any and all previous proxies and powers of attorney granted with respect to such Stockholder's Shares, and the Stockholder shall not grant any subsequent proxy or power of attorney with respect to such Stockholder's Shares, as agreed herein, The Stockholder hereby grants, or agrees to cause the applicable record holder to grant, a prox |
|
| May 3, 2022 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM PART II AND III.11.1 3 bdptex111.htm CONSENT OF INDEPENDENT EXHIBIT 11.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation in this Offering Statement on Form 1-A of our report dated March 30, 2022, relating to the financial statements of BioAdaptives, Inc. as of December 31, 2021 and 2020 and to all references to our firm included in this Registration |
|
| May 3, 2022 |
EXHIBIT 99.2 April 14, 2022 Ferris Holding, Inc 2251 N. Rampart Blvd., #182 Las Vegas, NV 89128 Re: License Agreements dated October 21, 2013 Dear Sirs: BioAdaptives, Inc. entered into two separate license agreements with Ferris Holding on October 21, 2013, permitting usage of Ferris’ Agronifier™ and related technology and proprietary products. These licenses each covered an initial six (6) month |
|
| May 3, 2022 |
NEWLAN LAW FIRM, PLLC 2201 Long Prairie Road, Suite 107-762 Flower Mound, Texas 75022 April 29, 2022 NEWLAN LAW FIRM, PLLC 2201 Long Prairie Road, Suite 107-762 Flower Mound, Texas 75022 940-367-6154 April 29, 2022 Jason Drory Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| May 3, 2022 |
RESOLUTION OF THE DIRECTORS OF BREATH OF LIFE FOUNDATION (WY 2016-000736983) EXHIBIT 99.3 RESOLUTION OF THE DIRECTORS OF BREATH OF LIFE FOUNDATION (WY 2016-000736983) The undersigned constitute a quorum of the directors of Breath of Life Foundation, a non-profit organization formed under provision of the Wyoming Non-Profit Corporation Act (the “Foundation”). The following minutes and resolutions set out the results of a telephonic meeting held on April 26, 2022. 1. The dir |
|
| May 3, 2022 |
1-A/A LIVE 0001575142 XXXXXXXX 024-11819 BIOADAPTIVES, INC. DE 2013 0001575142 2834 46-2592228 3 4 2620 Regatta Drive Suite 102 Las Vegas NV 89128 702-659-8829 2201 Long Prairie Road Other 82936.00 190.00 0.00 0.00 148585.00 247750.00 0.00 1241624.00 -1093039.00 148585.00 19776.00 9671.00 0.00 -1049948.00 -0.03 -0.03 BF Borgers CPA PC Common Stock 67367483 090724107 OTC Pink N/A 0 N/A N/A N/A 0 N/ |
|
| May 3, 2022 |
PART II AND III 2 bdpt1aa.htm FORM 1-A/A As filed with the Securities and Exchange Commission on May 2, 2022 PART II - INFORMATION REQUIRED IN OFFERING CIRCULAR Preliminary Offering Circular dated May 2, 2022 An offering statement pursuant to Regulation A relating to these securities has been filed with the United States Securities and Exchange Commission (the “SEC”). Information contained in this |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark one) ? Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For the fiscal year endedDecember 31, 2021 ? Transition Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54949 BioAdaptives, Inc. |
|
| March 30, 2022 |
United States securities and exchange commission logo March 30, 2022 Edward E. Jacobs, M.D. Chief Executive Officer Bioadaptives, Inc. 2620 Regatta Drive, Suite 102 Las Vegas, NV 89128 Re: Bioadaptives, Inc. Amendment No. 1 to Offering Statement on Form 1-A Filed March 18, 2022 File No. 024-11819 Dear Dr. Jacobs: We have reviewed your amended offering statement and have the following comment. In o |
|
| March 18, 2022 |
EXHIBIT 99.1 Irrevocable Proxy. The Stockholder hereby revokes any and all previous proxies and powers of attorney granted with respect to such Stockholder's Shares, and the Stockholder shall not grant any subsequent proxy or power of attorney with respect to such Stockholder's Shares, as agreed herein, The Stockholder hereby grants, or agrees to cause the applicable record holder to grant, a prox |
|
| March 18, 2022 |
2201 Long Prairie Road, Suite 107-762 Flower Mound, Texas 75022 March 17, 2022 NEWLAN LAW FIRM, PLLC 2201 Long Prairie Road, Suite 107-762 Flower Mound, Texas 75022 940-367-6154 March 17, 2022 Jason Drory Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| March 18, 2022 |
PART II AND III 2 bdpt1a.htm FORM 1-A/A As filed with the Securities and Exchange Commission on March 17 , 2022 PART II - INFORMATION REQUIRED IN OFFERING CIRCULAR Preliminary Offering Circular dated March 17 , 2022 An offering statement pursuant to Regulation A relating to these securities has been filed with the United States Securities and Exchange Commission (the “SEC”). Information contained |
|
| March 16, 2022 |
United States securities and exchange commission logo March 16, 2022 Edward E. Jacobs, M.D. Chief Executive Officer Bioadaptives, Inc. 2620 Regatta Drive, Suite 102 Las Vegas, NV 89128 Re: Bioadaptives, Inc. Offering Statement on Form 1-A Filed March 4, 2022 File No. 024-11819 Dear Dr. Jacobs: We have reviewed your offering statement and have the following comments. In some of our comments, we may |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement BIOADAPTIVES, INC. |
|
| March 4, 2022 |
EXHIBIT 2.7 |
|
| March 4, 2022 |
SUBSCRIPTION AGREEMENT Bioadaptives, Inc. NOTICE TO INVESTORS EX1A-4 SUBS AGMT.1 5 bdptex41.htm EX-4.1 EXHIBIT 4.1 SUBSCRIPTION AGREEMENT Bioadaptives, Inc. NOTICE TO INVESTORS The securities of Bioadaptives, Inc., a Nevada corporation (the “Company”), to which this Subscription Agreement relates, represent an investment that involves a high degree of risk, suitable only for persons who can bear the economic risk for an indefinite period of time and who can |
|
| March 4, 2022 |
EX1A-2A CHARTER 3 bdptex26.htm EX-2.6 EXHIBIT 2.6 |
|
| March 4, 2022 |
NEWLAN LAW FIRM, PLLC 2201 Long Prairie Road – Suite 107-762 Flower Mound, Texas 75022 March 1, 2022 EXHIBIT 12.1 NEWLAN LAW FIRM, PLLC 2201 Long Prairie Road ? Suite 107-762 Flower Mound, Texas 75022 940-367-6154 March 1, 2022 Bioadaptives, Inc. 2620 Regatta Drive Suite 102 Las Vegas, Nevada 89128 Re: Offering Statement on Form 1-A Gentlemen: We have been requested by Bioadaptives, Inc. a Nevada corporation (the ?Company?), to furnish you with our opinion as to the matters hereinafter set forth |
|
| March 4, 2022 |
EX1A-6 MAT CTRCT.7 8 bdptex67.htm EX-6.7 EXHIBIT 6.7 EMPLOYMENT CONTRACT THIS EMPLOYMENT CONTRACT is made effective July 1, 2021 (the Effective Date”), between BIOADAPTIVES, INC. (hereinafter referred to as “Employer”, or the Company), a Delaware corporation with it principal place of business in Las Vegas, Nevada and Dr. Edward E. Jacobs (hereinafter referred to as “Employee”) who resides in Las |
|
| March 4, 2022 |
As filed with the Securities and Exchange Commission on March 3, 2022 PART II - INFORMATION REQUIRED IN OFFERING CIRCULAR Preliminary Offering Circular dated March 3, 2022 An offering statement pursuant to Regulation A relating to these securities has been filed with the United States Securities and Exchange Commission (the ?SEC?). |
|
| March 4, 2022 |
EX1A-6 MAT CTRCT.4 7 bdptex64.htm EX-6.4 EXHIBIT 6.4 EMPLOYMENT CONTRACT THIS EMPLOYMENT AGREEMENT is made this 1st day of June, 2021(the Effective Date”), between BIOADAPTIVES, INC. (hereinafter referred to as "Employer", or the Company), a Delaware corporation with it principal place of business in Las Vegas, Nevada and ROBERT W. ELLIS (hereinafter referred to as "Employee") who resides in River |
|
| March 4, 2022 |
EXHIBIT 6.3 EMPLOYMENT CONTRACT THIS EMPLOYMENT AGREEMENT is made this 1st day of June, 2021(the Effective Date?), between BIOADAPTIVES, INC. (hereinafter referred to as ?Employer?, or the Company), a Delaware corporation with it principal place of business in Las Vegas, Nevada and CHARLES TOWNSEND (hereinafter referred to as ?Employee?) who resides in Lewisville, Texas. In consideration of the mu |
|
| February 3, 2022 |
February 2, 2022, Patent Purchaser Agreement and Consulting Agreement EXHIBIT 10.1 PATENT PURCHASE AGREEMENT AND CONSULTING AGREEMENT This PATENT PURCHASE AGREEMENT AND CONSULTING AGREEMENT (this ?Agreement?) is entered into, as of the Effective Date (defined below), by and between BioAdaptives, Inc., a Delaware corporation with principal offices in Las Vegas, Nevada (?Purchaser?), and Thomas J. Mohr, an individual who resides in Port St. Lucie, Florida (?Seller?). |
|
| February 3, 2022 |
EXHIBIT 99.1 BIOADAPTIVES ACQUIRES OXYGENATED WATER TECHNOLOGY PATENT AND FORMS SUBSIDIARY, MORO2, INC., TO CREATE NEW PRODUCTS Las Vegas, Nevada ? February 3, 2022. BioAdaptives, Inc. (OTCMkts: BDPT) announced today that it has entered into a definitive agreement with inventor Thomas J. Mohr to acquire his U.S. Patent 9,783,432B, which covers technology used in enhancing the capability of water t |
|
| February 3, 2022 |
FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 2, 2022 BIOADAPTIVES, INC. |
|
| January 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement BIOADAPTIVES, INC. |
|
| January 21, 2022 |
BIOADAPTIVES SIGNS LETTER OF INTENT TO ACQUIRE OXYGENATED WATER TECHNOLOGY PATENT EXHIBIT 99.1 BIOADAPTIVES SIGNS LETTER OF INTENT TO ACQUIRE OXYGENATED WATER TECHNOLOGY PATENT Las Vegas, Nevada - January 20, 2022. BioAdaptives, Inc. (OTCMkts: BDPT) announced today that it has entered into a Letter of Intent with inventor Thomas J. Mohr, to acquire rights to his U.S. Patent 9,783,432B, which covers technology used in enhancing the capability of water to hold significantly large |
|
| January 21, 2022 |
FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 20, 2022 BIOADAPTIVES, INC. |
|
| December 16, 2021 |
FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2021 BIOADAPTIVES, INC. |
|
| December 16, 2021 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE BIOADAPTIVES ? LUNGFLUTE? MARKETING AGREEMENT AND NEW PRODUCT Co-Marketing Initiative; LungArmor Sales Program Las Vegas, Nevada ? November XX, 2021. BioAdaptives, Inc. (OTCMkts: BDPT) announced that it has entered into a Marketing Agreement with Acoustic Innovations LLC, the developer of the LungFlute? OscPEP (Oscillating Positive Expiratory Pressure) medical de |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Commission File Number 000-54949 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction of incorporation or organ |
|
| August 27, 2021 |
BIOADAPTIVES collaboration with Stanford Professor EXHIBIT 99.1 FOR IMMEDIATE RELEASE BIOADAPTIVES collaboration with Stanford Professor PluriPain? studied for pain relief in Gadolinium toxicity patients Las Vegas, Nevada ?Aug 26, 2021. BioAdaptives, Inc. (OTCMkts: BDPT) announced the collaboration with Professor Lorrin Koran, M.D., Stanford Medical Center, Stanford, CA. Dr. Edward Jacobs, CEO, BioAdaptives, Inc., stated, ?Professor Koran, from th |
|
| August 27, 2021 |
FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 26, 2021 BIOADAPTIVES, INC. |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Commission File Number 000-54949 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction of incorporation or organizati |
|
| July 22, 2021 |
8-K 1 bdpt8k.htm FORM 8-K FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 22, 2021 BIOADAPTIVES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54949 46-2592228 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 2620 |
|
| July 22, 2021 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE BIOADAPTIVES - LIVESTOCK IMPACT DIVISION ANNOUNCEMENT Marketing Initiative and Ambassador Program Las Vegas, Nevada ? July 22, 2021. BioAdaptives, Inc. (OTCMkts: BDPT) announced that its Livestock Impact Division, the marketer of Equine All-in-One? and Canine Regen? products, has commenced an Ambassador Program outreach marketing program. The Ambassador Program p |
|
| June 11, 2021 |
EXHIBIT 99.11 FOR IMMEDIATE RELEASE BIOADAPTIVES COMMENCES SOCIAL MEDIA ROLL-OUT Targets markets for pain relief and anti-viral/immune defense applications Las Vegas, Nevada ? June 8, 2021. BioAdaptives, Inc. (OTCMkts: BDPT) announced the kick-off of its social media outreach advertising campaign. J Ramsdell Consulting, Syracuse New York, and The Dropup Agency, Dallas, Texas, have been brought on |
|
| June 11, 2021 |
EXHIBIT 99.12 BIOADAPTIVES MANAGEMENT ADDITIONS Las Vegas, Nevada ? June 10, 2021. BioAdaptives, Inc. (OTCMkts: BDPT) announced the appointment of Charles Townsend as Chief Operating Officer and as a director. Robert W. Ellis will remain as President and has also been appointed as a director. Ronald Lambrecht has been reappointed as Chief Financial Officer. Mr. Townsend brings over 30 years of exp |
|
| June 11, 2021 |
May 21, 2021, 2021 Equity Incentive Plan EXHIBIT 10.14 BioAdaptives, inc. (the ?Company?) 2021 INCENTIVE PLAN SECTION 1. PURPOSE The purpose of the BioAdaptives, Inc. 2021 Incentive Plan (the ?Plan?) is to attract, retain and motivate employees, officers, directors, consultants, agents, advisors and independent contractors of the Company and its Related Companies by providing them the opportunity to acquire a proprietary interest in the |
|
| June 11, 2021 |
May 31, 2021, Lambrecht Employment Contract EXHIBIT 10.13 EMPLOYMENT CONTRACT THIS EMPLOYMENT AGREEMENT is made this 31st day of May, 2021(the Effective Date?), between BIOADAPTIVES, INC. (hereinafter referred to as "Employer", or the Company), a Delaware corporation with it principal place of business in Las Vegas, Nevada and RONALD LAMBRECHT (hereinafter referred to as "Employee") who resides in Riverview, Florida. In consideration of the |
|
| June 11, 2021 |
FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2021 BIOADAPTIVES, INC. |
|
| June 11, 2021 |
May 31, 2021, Ellis Employment Contract EXHIBIT 10.12 EMPLOYMENT CONTRACT THIS EMPLOYMENT AGREEMENT is made this 31st day of May, 2021(the Effective Date?), between BIOADAPTIVES, INC. (hereinafter referred to as "Employer", or the Company), a Delaware corporation with it principal place of business in Las Vegas, Nevada and ROBERT W. ELLIS (hereinafter referred to as "Employee") who resides in Riverview, Florida. In consideration of the |
|
| June 11, 2021 |
May 31, 2021, Townsend Employment Contract EXHIBIT 10.11 EMPLOYMENT CONTRACT THIS EMPLOYMENT AGREEMENT is made this 31st.day of May, 2021(the Effective Date"), between BIOADAPTIVES, INC. (hereinafter referred to as "Employer", or the Company), a Delaware corporation with it principal place of business in Las Vegas, Nevada and CHARLES TOWNSEND (hereinafter referred to as "Employee") who resides in Lewisville, Texas. In consideration of the |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 bdpt10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Commission File Number 000-54949 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark one) ? Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 ? Transition Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54949 BioAdaptives, Inc. |
|
| November 16, 2020 |
10-Q 1 bdpt10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File |
|
| August 13, 2020 |
10-Q 1 bdpt10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| June 16, 2020 |
BIOADAPTIVES PRODUCT ROLL-OUT: LIVESTOCK IMPACT EXHIBIT 99.1 BIOADAPTIVES PRODUCT ROLL-OUT: LIVESTOCK IMPACT™ EQUINE ALL-IN-ONE™ INTRODUCED AT SHAWNEE SPRING HORSE SALE Equine feed supplement improves performance/appearance – Great initial reports Las Vegas, Nevada – June 16, 2020/ /EINPresswire.com/ - BioAdaptives, Inc. (OTCMkts: BDPT) rolled out its LiveStock Impact™ Equine All-in-One™ feed supplement at the Spring Horse Sale in Shawnee, Okla |
|
| June 16, 2020 |
FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2020 BIOADAPTIVES, INC. |
|
| June 11, 2020 |
Quarterly Report - FORM 10-Q AMENDMENT NO. 1 10-Q/A 1 bdpt10qa1.htm FORM 10-Q AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q / A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tran |
|
| June 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54949 BioAdaptives Inc |
|
| May 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K/A (Mark one) x Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 ☐ Transition Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54949 BioAdaptives, Inc. |
|
| May 11, 2020 |
FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2020 BIOADAPTIVES, INC. |
|
| May 1, 2020 |
10-K 1 bdpt10k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark one) x Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 ☐ Transition Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54949 Bi |
|
| March 30, 2020 |
FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2020 BIOADAPTIVES, INC. |
|
| March 4, 2020 |
BDPT / Bioadaptives, Inc. DEF 14C - - DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement BIOADAPTIVES, INC. |
|
| February 11, 2020 |
FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2020 BIOADAPTIVES, INC. |
|
| February 11, 2020 |
Certificate of Designation establishing Series A Preferred Stock EXHIBIT 3.1 BIOADAPTIVES, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW BIOADAPTIVES, INC. a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify that, in accor |
|
| February 11, 2020 |
Amended Certificate of Incorporation EXHIBIT 3.2 |
|
| February 10, 2020 |
BDPT / Bioadaptives, Inc. PRE 14C - - PRE 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ¨ Definitive Information Statement BIOADAPTIVES, INC. |
|
| November 6, 2019 |
BDPT / Bioadaptives, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54949 BioAdaptives |
|
| September 27, 2019 |
BioAdaptives, Inc. Announces Return to Fully Reporting and Appointment of President EX-99.1 2 baex99z1.htm PRESS RELEASE 99.1 Press Release of BioAdaptives, Inc dated September 11, 2019 BioAdaptives, Inc. Announces Return to Fully Reporting and Appointment of President LAS VEGAS, Nev., Sept. 11, 2019 (SEND2PRESS NEWSWIRE) - BioAdaptives, Inc. (OTC BB: BDPT) announced the Company’s return to a fully-reporting entity, and the appointment of Mr. Robert W. Ellis as its new President, |
|
| September 27, 2019 |
BIOADAPTIVES, INC. Announces new majority-owned Subsidiary Press Release 99.2 Press Release of BioAdaptives, Inc dated September 18, 2019 BIOADAPTIVES, INC. Announces new majority-owned Subsidiary Las Vegas Nevada, September 18, 2019/ EINPRESSWIRE/ – Bioadaptives, Inc. (OTC BB: BDPT) announced the Company’s formation of Livestock Impact, Inc., a majority-owned subsidiary, created to optimize BioAdaptive’s plan to become a leading distributor of nutritiona |
|
| September 27, 2019 |
8-K 1 ba8k.htm CURRENT EVENT REPORT - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): September 11, 2019 BioAdaptives Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54949 46-2592228 (State or other jurisdi |
|
| September 27, 2019 |
BIOADAPTIVES, INC announces TizHemp, a new Hemp-product Division & appointment of new CFO Press Release 99.3 Press Release of BioAdaptives, Inc dated September 24, 2019 BIOADAPTIVES, INC announces TizHemp, a new Hemp-product Division & appointment of new CFO Las Vegas Nevada, September 24, 2019 (Globe Newswire) – via Newmediawire – Bioadaptives, Inc. (OTC BB: BDPT) announced the Company’s formation of TizHemp, a new operating division to concentrate efforts on wellness- related hemp-ba |
|
| August 14, 2019 |
BDPT / Bioadaptives, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54949 BioAdaptives Inc. |
|
| August 1, 2019 |
August 1, 2019 Edward E. Jacobs, Jr. Chief Executive Officer BioAdaptives, Inc. 4385 Cameron St., Suite B Las Vegas, NV 89103 Re: BioAdaptives, Inc. Form 10-12G Filed May 10, 2019 File No. 000-54949 Dear Mr. Jacobs: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any r |
|
| August 1, 2019 |
BDPT / Bioadaptives, Inc. TEXT-EXTRACT - - August 1, 2019 Edward E. Jacobs, Jr. Chief Executive Officer BioAdaptives, Inc. 4385 Cameron St., Suite B Las Vegas, NV 89103 Re: BioAdaptives, Inc. Form 10-12G Filed May 10, 2019 File No. 000-54949 Dear Mr. Jacobs: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any r |
|
| July 23, 2019 |
Product License with Ferris Holding for the trade secret and proprietary products EXHIBIT 10.2 LICENSE AGREEMENT THIS LICENSE AGREEMENT (the "Agreement") is entered into by and between Ferris Holding, Inc. a Nevada corporation ("Licensor"), and BioAdaptives, Inc., a Delaware corporation ("Licensee"). SECTION 1: SCOPE OF THIS AGREEMENT 1.1 This licensing agreement allows Licensee the non-exclusive use of Licensor's trade secrets regarding its proprietary products, including its |
|
| July 23, 2019 |
Technology License with Ferris Holding for the use of trade secret of Agronifier EXHIBIT 10.1 LICENSE AGREEMENT THIS LICENSE AGREEMENT (the "Agreement") is entered into by and between Ferris Holding, Inc. a Nevada corporation ("Licensor"), and BioAdaptives, Inc., a Delaware corporation ("Licensee"). SECTION 1: SCOPE OF THIS AGREEMENT 1.1 This licensing agreement allows Licensee the non-exclusive use of Licensor's trade secrets regarding its proprietary Agronifier™ processes, m |
|
| July 23, 2019 |
Amended and Restated Certificate of Incorporation -Certified EXHIBIT 3.2 1 2 |
|
| July 23, 2019 |
EXHIBIT 3.3 AMENDED AND RESTATED BY LAW OF BIOADPTIVES, INC ARTICLE I - OFFICES Section 1. The registered office of the corporation in the State of Delaware shall be at 16192 Coastal Highway, in the city of Lewes, County of Sussex, Delaware, 19958. The registered agent in charge thereof shall be Harvard Business Services, Inc. Section 2. The corporation may also have offices at such other places a |
|
| July 23, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 2 ) GENERAL FORM FOR REGISRATION OF SECURITIES Pursuant to Section 12(b) or (g) of The Securities Exchange Act of 1934 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identificat |
|
| July 23, 2019 |
CORRESP 11 filename11.htm July 22, 2019 Division of Corporate Finance Office of Manufacturing and Construction United States Securities and Exchange Commission Washington, D.C. 20549 RE: BIOADAPTIVES, INC Amendment No 1 Form 10-12(g) Filed June 27, 2019 File No. 000-54949 Dear Sirs/Madam This correspondence is in response to your letter dated July 10, 2019 in reference to our filing of the Form 10 |
|
| July 23, 2019 |
Certificate of Incorporation of the Registrant EX-3.1 2 bioadaptivesex31.htm EX-3.1 EXHIBIT 3.1 |
|
| July 10, 2019 |
BDPT / Bioadaptives, Inc. TEXT-EXTRACT - - July 10, 2019 Edward E. Jacobs, Jr. Chief Executive Officer BioAdaptives, Inc. 4385 Cameron St., Suite B Las Vegas, NV 89103 Re: BioAdaptives, Inc. Amendment No. 1 to Form 10-12G Filed June 27, 2019 File No. 000-54949 Dear Mr. Jacobs: We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your |
|
| July 10, 2019 |
July 10, 2019 Edward E. Jacobs, Jr. Chief Executive Officer BioAdaptives, Inc. 4385 Cameron St., Suite B Las Vegas, NV 89103 Re: BioAdaptives, Inc. Amendment No. 1 to Form 10-12G Filed June 27, 2019 File No. 000-54949 Dear Mr. Jacobs: We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your |
|
| June 27, 2019 |
EX-3.3 4 bioadaptivesex33.htm EX-3.3 EXHIBIT 3.3 AMENDED AND RESTATED BY LAW OF BIOADPTIVES, INC ARTICLE I - OFFICES Section 1. The registered office of the corporation in the State of Delaware shall be at 16192 Coastal Highway, in the city of Lewes, County of Sussex, Delaware, 19958. The registered agent in charge thereof shall be Harvard Business Services, Inc. Section 2. The corporation may als |
|
| June 27, 2019 |
Certificate of Incorporation of the Registrant EX-3.1 2 bioadaptivesex31.htm EX-3.1 EXHIBIT 3.1 |
|
| June 27, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 1) GENERAL FORM FOR REGISRATION OF SECURITIES Pursuant to Section 12(b) or (g) of The Securities Exchange Act of 1934 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identificati |
|
| June 27, 2019 |
Amended and Restated Certificate of Incorporation -Certified EXHIBIT 3.2 1 2 |
|
| June 27, 2019 |
Product License with Ferris Holding for the trade secret and proprietary products EXHIBIT 10.2 LICENSE AGREEMENT THIS LICENSE AGREEMENT (the "Agreement") is entered into by and between Ferris Holding, Inc. a Nevada corporation ("Licensor"), and BioAdaptives, Inc., a Delaware corporation ("Licensee"). SECTION 1: SCOPE OF THIS AGREEMENT 1.1 This licensing agreement allows Licensee the non-exclusive use of Licensor's trade secrets regarding its proprietary products, including its |
|
| June 27, 2019 |
CORRESP 11 filename11.htm June 27, 2019 Division of Corporate Finance Office of Manufacturing and Construction United States Securities and Exchange Commission Washington, D.C. 20549 RE: BIOADAPTIVES, INC Form 10-12(g) Filed May 10, 2019 File No. 000-54949 Dear Sirs/Madam This correspondence is in response to your letter dated June 6, 2019 in reference to our filing of the Form 10 filed May 10, 20 |
|
| June 27, 2019 |
Technology License with Ferris Holding for the use of trade secret of Agronifier EX-10.1 5 bioadaptivesex101.htm EX-10.1 EXHIBIT 10.1 LICENSE AGREEMENT THIS LICENSE AGREEMENT (the "Agreement") is entered into by and between Ferris Holding, Inc. a Nevada corporation ("Licensor"), and BioAdaptives, Inc., a Delaware corporation ("Licensee"). SECTION 1: SCOPE OF THIS AGREEMENT 1.1 This licensing agreement allows Licensee the non-exclusive use of Licensor's trade secrets regarding |
|
| June 6, 2019 |
BDPT / Bioadaptives, Inc. TEXT-EXTRACT - - June 6, 2019 Edward E. Jacobs, Jr. Chief Executive Officer BioAdaptives, Inc. 4385 Cameron St., Suite B Las Vegas, NV 89103 Re: BioAdaptives, Inc. Form 10-12G Filed May 10, 2019 File No. 000-54949 Dear Mr. Jacobs: We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please r |
|
| June 6, 2019 |
June 6, 2019 Edward E. Jacobs, Jr. Chief Executive Officer BioAdaptives, Inc. 4385 Cameron St., Suite B Las Vegas, NV 89103 Re: BioAdaptives, Inc. Form 10-12G Filed May 10, 2019 File No. 000-54949 Dear Mr. Jacobs: We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please r |
|
| May 10, 2019 |
BDPT / Bioadaptives, Inc. 10-12G 10-12G 10-12G 1 bioadaptives1012g.htm 10-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISRATION OF SECURITIES Pursuant to Section 12(b) or (g) of The Securities Exchange Act of 1934 BioAdaptives Inc. (Exact name of registrant as specified in its charter) Delaware 46-2592228 (State or other jurisdiction of incorporation or organization) (I.R.S. Emp |
|
| March 31, 2017 |
bioadaptives15d.htm UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0167 Expires: March 31, 2018 Estimated average burden hours per response?.1.50 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SEC |
|
| November 18, 2016 |
Bioadaptives FORM 10-Q (Quarterly Report) 10-Q 1 bioadaptives10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi |
|
| November 14, 2016 |
edgarproof.pdf UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-54949 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check one): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K |
|
| August 18, 2016 |
Bioadaptives 10-Q (Quarterly Report) 10-Q 1 bioadaptives10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x Quarterly report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2016 ¨ Transition report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to 000-54949 (Commission file numbe |
|
| August 16, 2016 |
NT 10-Q 1 2015jun30-bdptnt10q.htm FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-54949 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2016 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Tran |
|
| May 23, 2016 |
Bioadaptives FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2016 ? Transition report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to 000-54949 (Commission file number) BioAdaptives Inc. (Exact nam |
|
| May 17, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-54949 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Repor |
|
| April 14, 2016 |
Bioadaptives FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number : 000-54949 BioAdaptives Inc. (Exact name of registrant as specified in its chart |
|
| March 31, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-54949 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Re |
|
| January 5, 2016 |
Bioadaptives SC 13D/A (Activist Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 1) Under The Securities Exchange Act of 1934 BioAdaptives Inc. F/K/A APEX 8 Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) Applied For (CUSIP Number) Richard Chiang 460 Brannan Street, Suite 78064 San Francisco, CA 94107 Telephone: (415) 713 6957 Ema |
|
| January 5, 2016 |
Bioadaptives SC 13D (Activist Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under The Securities Exchange Act of 1934 BioAdaptives Inc. F/K/A APEX 8 Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) Applied For (CUSIP Number) Richard Chiang 460 Brannan Street, Suite 78064 San Francisco, CA 94107 Telephone: (415) 713 6957 Email: [email protected] |
|
| November 23, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2015 ? Transition report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to 000-54949 (Commission file number) BioAdaptives Inc. (Exact |
|
| November 16, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-54949 NOTIFICATION OF LATE FILING CUSIP NUMBER (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition R |
|
| August 21, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2015 ? Transition report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to 000-54949 (Commission file number) BioAdaptives Inc. (Exact name |
|
| August 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 000-54949 CUSIP NUMBER (Check one): o Form 10-K o Form 20-F o Form 11-K ? Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2015 o Transition Report on Form 10 |
|
| May 20, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2015 ? Transition report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to 000-54949 (Commission file number) BioAdaptives Inc. (Exact nam |
|
| May 18, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 000-54949 CUSIP NUMBER (Check one): o Form 10-K o Form 20-F o Form 11-K ? Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2015 o Transition Report on Form 1 |
|
| April 23, 2015 |
April 23, 2015 U.S. Securities and Exchange Commission Office of the Chief Accountant 100F Street Northeast Washington, DC 20549-2000 RE: BioAdaptives, Inc. File No. 000-54949 Dear Sir or Madam: We have read Item 4.01 of Form 8-K dated April 23, 2015 of BioAdaptives, Inc. and are in agreement with the statements contained therein as it pertains to our firm. We have no basis to agree or disagree wi |
|
| April 23, 2015 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 23, 2015 BioAdaptives Inc. (EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER) Delaware 000-54949 46-2592228 (STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION) (COMMI |
|
| April 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K 10-K 1 bioadaptives10k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-54949 BioAdaptives Inc. (Exact name of |
|
| March 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response ... 2.50 000-54949 SEC FILE NUMBER (Check one): ? Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2014 o Transition R |
|
| February 6, 2015 |
BioAdaptives (OTCBB:BDPT) Announces New President EX-99 4 ex991.htm EXHIBIT 99.1 BioAdaptives (OTCBB:BDPT) Announces New President LAS VEGAS, Feb. 6, 2015 - BioAdaptives, Inc., a fully-reporting public company trading under the ticker symbol: (OTCBB: BDPT), announced that Mr. Christopher G. Hall has been selected to lead the company going forward as its new President, with additional titles of Chief Executive Officer, Chief Financial Officer, and |
|
| February 6, 2015 |
8-K 1 bdpt8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): February 6, 2015 BioAdaptives Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54949 46-2592228 (State or other jurisdiction of incorporation) |
|
| February 6, 2015 |
EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT dated this 6th day of February, 2015 BETWEEN: BioAdaptives Inc. |
|
| February 6, 2015 |
BIOADAPTIVES, INC. RESTRICTED STOCK AGREEMENT * * * * * BIOADAPTIVES, INC. RESTRICTED STOCK AGREEMENT * * * * * Recipient: Christopher G. Hall Grant Date: February 6, 2015 Number of Shares of Common Stock Subject to this Restricted Stock Grant: 100,000 Vesting Schedule: None Eligible for Rule 144: July 6, 2015 This Restricted Stock Agreement (this “Agreement”), dated as of the Grant Date specified above, is between BioAdaptives Inc., a Delaware corpora |
|
| November 14, 2014 |
EX-10 6 ex1014.htm EXHIBIT 10.14 LOAN AGREEMENT This Loan Agreement (the “Loan Agreement”) is made as of this 2nd, day of July, 2014, by and between Ferris Holding Inc., a Nevada corporation (“Creditor”), and BioAdaptives, Inc., a Delaware corporation (“Debtor”). The Creditor and Debtor may each be referred to herein as a “Party” and collectively as the “Parties.” R E C I T A L S A. The Creditor, |
|
| November 14, 2014 |
LOAN AGREEMENT This Loan Agreement (the ?Loan Agreement?) is made as of this 4th, day of June, 2014, by and between Ferris Holding Inc. |
|
| November 14, 2014 |
EX-10 2 exhibit1010.htm EXHIBIT 10.10 LICENSE AGREEMENT THIS LICENSE AGREEMENT (the "Agreement") is entered into by and between Ferris Holding, Inc. a Nevada corporation ("Licensor"), and BioAdaptives, Inc., a Delaware corporation ("Licensee"). SECTION 1: SCOPE OF THIS AGREEMENT 1.1 This licensing agreement allows Licensee the non-exclusive use of Licensor's trade secrets regarding its proprietary |
|
| November 14, 2014 |
10-Q 1 bioadaptive10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2014 [] Transition report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to 000-54949 (Commissio |
|
| November 14, 2014 |
EX-10 4 ex1012.htm EXHIBIT 10.12 LOAN AGREEMENT This Loan Agreement (the “Loan Agreement”) is made as of this 23rd, day of April, 2014, by and between Ferris Holding Inc., a Nevada corporation (“Creditor”), and BioAdaptives, Inc., a Delaware corporation (“Debtor”). The Creditor and Debtor may each be referred to herein as a “Party” and collectively as the “Parties.” R E C I T A L S A. The Creditor |
|
| November 14, 2014 |
EX-10 3 ex1011.htm EXHIBIT 10.11 RENTAL AGREEMENT This Rental Agreement (the “Rental Agreement”) is made as of this 1st, day of June, 2014, by and between Ferris Holding Inc., a Nevada corporation (“Lessor”), and BioAdaptives, Inc., a Delaware corporation (“Lessee”). The Creditor and Debtor may each be referred to herein as a “Party” and collectively as the “Parties.” R E C I T A L S A. The Lessor |
|
| August 14, 2014 |
BIOADAPTIVES, INC. RESTRICTED STOCK AGREEMENT * * * * * BIOADAPTIVES, INC. RESTRICTED STOCK AGREEMENT * * * * * Recipient: Gerald Epling Grant Date: April 10, 2014 Number of Shares of Common Stock Subject to this Restricted Stock Grant: 100,000 Vesting Schedule: None Eligible for Rule 144: October 10, 2014 1 This Restricted Stock Agreement (this “Agreement”), dated as of the Grant Date specified above, is between BioAdaptives Inc., a Delaware corporati |
|
| August 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2014 [] Transition report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to 000-54949 (Commission file number) BioAdaptives Inc. (Exact n |
|
| August 14, 2014 |
BIOADAPTIVES, INC. RESTRICTED STOCK AGREEMENT * * * * * EX-10 4 ex105.htm EXHIBIT 10.5 BIOADAPTIVES, INC. RESTRICTED STOCK AGREEMENT * * * * * Recipient: Jun Gu Grant Date: April 10, 2014 Number of Shares of Common Stock Subject to this Restricted Stock Grant: 150,000 Vesting Schedule: None Eligible for Rule 144: October 10, 2014 1 This Restricted Stock Agreement (this “Agreement”), dated as of the Grant Date specified above, is between BioAdaptives In |
|
| August 14, 2014 |
BIOADAPTIVES, INC. RESTRICTED STOCK AGREEMENT * * * * * BIOADAPTIVES, INC. RESTRICTED STOCK AGREEMENT * * * * * Recipient: Antonia Nabokava Grant Date: April 10, 2014 Number of Shares of Common Stock Subject to this Restricted Stock Grant: 100,000 Vesting Schedule: None Eligible for Rule 144: October 10, 2014 1 This Restricted Stock Agreement (this “Agreement”), dated as of the Grant Date specified above, is between BioAdaptives Inc., a Delaware corpor |
|
| August 14, 2014 |
BIOADAPTIVES, INC. RESTRICTED STOCK AGREEMENT * * * * * BIOADAPTIVES, INC. RESTRICTED STOCK AGREEMENT * * * * * Recipient: Ted Jacobs Grant Date: April 10, 2014 Number of Shares of Common Stock Subject to this Restricted Stock Grant: 100,000 Vesting Schedule: None Eligible for Rule 144: October 10, 2014 1 This Restricted Stock Agreement (this ?Agreement?), dated as of the Grant Date specified above, is between BioAdaptives Inc., a Delaware corporation |
|
| August 14, 2014 |
BIOADAPTIVES, INC. RESTRICTED STOCK AGREEMENT * * * * * EX-10 7 ex108.htm EXHIBIT 10.8 BIOADAPTIVES, INC. RESTRICTED STOCK AGREEMENT * * * * * Recipient: Gracie Homsey Grant Date: April 10, 2014 Number of Shares of Common Stock Subject to this Restricted Stock Grant: 100,000 Vesting Schedule: None Eligible for Rule 144: October 10, 2014 1 This Restricted Stock Agreement (this “Agreement”), dated as of the Grant Date specified above, is between BioAdapt |
|
| July 15, 2014 |
BioAdaptives Prepares for Next Step Exhibit 99.1 BioAdaptives Prepares for Next Step LAS VEGAS, July 14, 2014 /PRNewswire via COMTEX/ - BioAdaptives, Inc. (OTCBB:BDPT) is pleased to announce Mr. Barry Epling, Chairman has assumed the roles of President and CEO of the Company. Mr. Epling is the owner of Ferris Holding, Inc., the company that licensed its formulation, intellectual properties, and other technologies to BioAdaptives, In |
|
| July 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): July 13, 2014 BioAdaptives Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54949 46-2592228 (State or other jurisdiction of incorporation) (Commission File Number) (I. |
|
| July 10, 2014 |
BioAdaptives OTC Bulletin Board Symbol: BDPT EX-99 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 BioAdaptives OTC Bulletin Board Symbol: BDPT BioAdaptives Inc. cleared by FINRA for quotation on OTC Bulletin Board and OTC Link under the symbol BDPT LAS VEGAS, Nevada, July 9, 2014-BioAdaptives, Inc. (OTC BB: BDPT) announced that it is cleared by FINRA for quotation on OTC Bulletin Board and OTC Link under the symbol BDPT effective as of July 8, 2014. |
|
| July 10, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported) July 8, 2014 BioAdaptives Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54949 46-2592228 (State or other jurisdiction of incorporation) (Commission File Number) (I.R. |
|
| May 23, 2014 |
STOCK SALE AND PURCHASE AGREEMENT STOCK SALE AND PURCHASE AGREEMENT THIS STOCK SALE AND PURCHASE AGREEMENT (the “Agreement”) is entered into and effective as of the 21st day of May, 2014 (the “Effective Date”), by and between BioAdaptives, Inc. |
|
| May 23, 2014 |
8-K 1 biadaptive8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported) May 20, 2014 BioAdaptives Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-54949 46-2592228 (State or other jurisdiction of incorporation |
|
| May 23, 2014 |
Kenne Ruan, CPA, P.C. Phone: (203) 824-0441 Fax: (203) 413-6486 40 Hemlock Hollow Road, Woodbridge, CT 06525 Web: [email protected] May 20, 2014 Office of the Chief Accountant Securities and Exchange Commission 100F Street, NE Washington, D.C. 20549 Dear Sir/Madam: We have read the statements made by BioAdaptives, Inc. (the Company), which were provided to us and which we understand will be filed |
|
| May 20, 2014 |
10-Q/A 1 bioaq12014.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A [X] Quarterly report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2014 [] Transition report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to 000-54949 (Commission fi |
|
| May 20, 2014 |
10-Q 1 bioaq12014.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] Quarterly report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2014 [] Transition report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to 000-54949 (Commission file n |
|
| May 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response ... 2.50 000-54949 SEC FILE NUMBER (Check one): o Form 10-K o Form 20-F o Form 11-K ý Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2014 o Transition Repo |
|
| April 14, 2014 |
ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this ?Agreement?) is entered into as of October 21, 2013, by and between BIOADAPTIVES, INC. |
|
| April 14, 2014 |
LICENSE AGREEMENT THIS LICENSE AGREEMENT (the "Agreement") is entered into by and between Ferris Holding, Inc. |
|
| April 14, 2014 |
LICENSE AGREEMENT THIS LICENSE AGREEMENT (the "Agreement") is entered into by and between Ferris Holding, Inc. |
|
| April 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-54949 BioAdaptives, Inc. (Exact name of re |
|
| March 28, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response ... 2.50 000-54949 SEC FILE NUMBER (Check one): ý Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2013 o Transition R |
|
| March 7, 2014 |
2,005,000 Shares BIOADAPTIVES, INC. Common Stock For a Distribution to Hemp, Inc., Shareholders 424B3 1 bio424b3.htm 424B3 2,005,000 Shares BIOADAPTIVES, INC. Common Stock For a Distribution to Hemp, Inc., Shareholders Hemp, Inc., a Colorado corporation (“Hemp”), is distributing to its shareholders 2,000,000 shares of Common Stock of BioAdaptives, Inc. (the “Company” or “BioAdaptives”), owned by Hemp, a shareholder of BioAdaptives. The shareholders of Hemp will receive one share of BioAdapti |
|
| January 14, 2014 |
2,005,000 Shares BIOADAPTIVES, INC. Common Stock For a Distribution to Hemp, Inc., Shareholders 2,005,000 Shares BIOADAPTIVES, INC. Common Stock For a Distribution to Hemp, Inc., Shareholders Hemp, Inc., a Colorado corporation (“Hemp”), is distributing to its shareholders 2,000,000 shares of Common Stock of BioAdaptives, Inc. (the “Company” or “BioAdaptives”), owned by Hemp, a shareholder of BioAdaptives. The shareholders of Hemp will receive one share of BioAdaptives common stock for every |
|
| January 7, 2014 |
SUBSIDIARIES OF THE REGISTRANT EXHIBIT 21 SUBSIDIARIES OF THE REGISTRANT Blender’s Choice Inc., a Nevada corporation |
|
| January 7, 2014 |
As filed with the United States Securities and Exchange Commission on January , 2014 Registration No. |
|
| December 2, 2013 |
SUBSIDIARIES OF THE REGISTRANT EXHIBIT 21 SUBSIDIARIES OF THE REGISTRANT Blender’s Choice Inc., a Nevada corporation |
|
| December 2, 2013 |
Registration Statement - FORM S-1 As filed with the United States Securities and Exchange Commission on November 29, 2013 Registration No. |
|
| October 25, 2013 |
EX-10 2 ex101.htm EXHIBIT 10.1 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this “Agreement”) is entered into as of October 21, 2013, by and between BIOADAPTIVES, INC., a Delaware corporation (“Buyer”), and BIOSWAN, INC., a Nevada corporation (“Seller”). Buyer and Seller are referred to collectively herein as the “Parties” and individually as a “Party.” RECITALS A. Seller is a biotechno |
|
| October 25, 2013 |
LICENSE AGREEMENT THIS LICENSE AGREEMENT (the "Agreement") is entered into by and between Ferris Holding, Inc. |
|
| October 25, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): October 21, 2013 BIOADAPTIVES, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER) Delaware 000-54949 46-2592228 (STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION) (CO |
